Adcock flags profit growth as colds and flu return
The firm said in June its trading environment had improved amid greater demand for over-the-counter and consumer healthcare products
18 August 2022 - 11:47
Adcock Ingram, which counts Panado painkillers and the cold and flu product Corenza C among its products, has flagged profit growth of at least a fifth in its year to end-June, benefiting from improved demand for over-the-counter products.
Headline earnings per share (HEPS) are expected to increase by 23.5%-24% to as much as 502c to end-June, the firm said in a brief trading update, with earnings per share expected to rise by between 24%-25%...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.